Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

ATAI Life Sciences BV

Healthcare US ATAI

4.53USD
-0.28(5.82%)

Last update at 2026-06-03T20:29:00Z

Day Range

4.464.78
LowHigh

52 Week Range

1.296.75
LowHigh

Fundamentals

  • Previous Close 4.81
  • Market Cap1787.26M
  • Volume4802068
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-110.21600M
  • Revenue TTM4.09M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM -43.51900M
  • Diluted EPS TTM-2.91

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -659.84900M -150.40500M -42.87900M -135.18200M -136.60100M
Minority interest 0.10M 0.78M 4.46M -5.03200M 6.44M
Net income -660.04700M -149.26900M -40.22400M -141.41100M -132.61200M
Selling general administrative 65.09M 47.54M 63.58M 70.35M 92.75M
Selling and marketing expenses - - 0.00000M - -
Gross profit 3.08M 0.31M 0.31M 0.23M 20.38M
Reconciled depreciation 1.01M 0.47M 0.27M 0.17M 0.05M
Ebit -114.06100M -145.28100M -36.63000M -144.78700M -135.80500M
Ebitda -113.04900M -144.80800M -36.31100M -144.07300M -104.84500M
Depreciation and amortization 1.01M 0.47M 0.32M 0.71M 30.96M
Non operating income net other - - - -6.40100M -
Operating income -114.06100M -102.69100M -125.47100M -144.78700M -135.80500M
Other operating expenses 118.15M 103.00M 125.78M 144.66M 140.70M
Interest expense 1.16M 3.12M 2.66M 1.92M 66.91M
Tax provision 0.30M -0.35600M 6.59M 6.23M -3.98900M
Interest income 1.48M 0.78M 1.38M 0.55M 0.20M
Net interest income 0.32M -2.34600M -0.58700M 0.55M 0.20M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.30M -0.35600M 1.02M 6.23M -3.98900M
Total revenue 4.09M 0.31M 0.31M 0.23M 20.38M
Total operating expenses 117.14M 103.00M 125.78M 144.66M 140.70M
Cost of revenue 1.01M 0.47M 0.32M - -
Total other income expense net -545.78800M -47.71400M 82.59M 9.61M -0.79600M
Discontinued operations - - - - -
Net income from continuing ops -660.14700M -150.04900M -71.40200M -141.41100M -174.24400M
Net income applicable to common shares - - - -152.38500M -167.80800M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 310.54M 159.39M 293.48M 305.44M 414.17M
Intangible assets 11.59M 3.25M - - -
Earning assets - - - - -
Other current assets 5.22M 16.45M 29.08M 14.04M 11.90M
Total liab 88.54M 42.83M 49.16M 300.42M 405.12M
Total stockholder equity 221.87M 116.30M 242.96M 260.74M -348.13700M
Deferred long term liab - - - - -
Other current liab 16.78M 12.31M 14.54M 17.50M 14.93M
Common stock 3.63M 18.79M 18.57M 18.56M 18.00M
Capital stock 3.63M 18.79M 18.57M 18.56M 18.00M
Retained earnings -1360.25400M -700.20700M -550.93800M -510.18800M -357.80300M
Other liab - - - 2.26M 6.53M
Good will 0.33M 0.33M - - -
Other assets - - - 10.61M 11.18M
Cash 85.30M 17.50M 45.03M 190.61M 362.27M
Cash and equivalents - - - - -
Total current liabilities 23.48M 24.95M 20.12M 19.90M 20.93M
Current deferred revenue 1.52M - 0.72M - -
Net debt -83.22800M 7.20M -28.55800M -175.49600M -361.52300M
Short term debt 0.27M 9.84M 0.28M - -
Short long term debt - 9.36M - - -
Short long term debt total 2.07M 24.71M 16.48M 15.12M 0.74M
Other stockholder equity 1599.42M 816.18M 794.79M 774.07M 348.14M
Property plant equipment - - - 0.93M 0.15M
Total current assets 275.68M 80.12M 185.59M 287.14M 375.08M
Long term investments 8.73M 70.97M 91.66M 14.02M 27.76M
Net tangible assets - - - 260.74M 376.91M
Short term investments 170.74M 44.83M 109.22M 82.50M -
Net receivables 14.43M 1.35M 2.26M 5.63M 0.91M
Long term debt - 14.13M 17.88M 14.70M 0.74M
Inventory - - 0.00000M - -
Accounts payable 4.91M 2.62M 4.59M 2.40M 6.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - 5.03M -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -20.92600M -18.46600M -19.46000M -21.70200M -8.33600M
Additional paid in capital - - - - -
Common stock total equity - - - 18.56M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - -510.18800M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.21M 0.85M 2.72M 10.61M 11.18M
Deferred long term asset charges - - - - -
Non current assets total 34.86M 79.26M 107.89M 18.30M 39.08M
Capital lease obligations 2.07M 1.21M 1.26M - -
Long term debt total - - - 14.70M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -92.89500M 59.17M 27.58M -85.82400M -81.27600M
Change to liabilities - - - -1.81300M 2.31M
Total cashflows from investing activities -109.12700M 59.17M -53.29500M -86.84800M -81.27600M
Net borrowings 0.00000M 5.00M 0.00000M 17.89M 1.59M
Total cash from financing activities 269.48M 5.37M -8.35500M 20.79M 409.86M
Change to operating activities - - - -0.30100M -9.91600M
Net income -660.04700M -150.04900M -43.89500M -157.41700M -174.24400M
Change in cash 57.80M -17.52900M -145.57900M -171.65300M 265.02M
Begin period cash flow 27.50M 45.03M 190.61M 362.27M 97.25M
End period cash flow 85.30M 27.50M 45.03M 190.61M 362.27M
Total cash from operating activities -102.67500M -82.43700M -84.11800M -104.46700M -63.24600M
Issuance of capital stock 258.13M 0.00000M 0.00000M 0.60M 409.88M
Depreciation 1.01M 0.47M 0.32M 0.17M 0.05M
Other cashflows from investing activities -13.00000M -8.10400M -5.84400M -0.25100M -2.55300M
Dividends paid - - - - -
Change to inventory - - 2.01M - -
Change to account receivables - -5.74500M -2.01400M - -
Sale purchase of stock -6.63500M 0.00000M - 2.29M -
Other cashflows from financing activities -21.66300M -0.16100M -8.35500M 16.15M -0.02200M
Change to netincome - - - 41.74M 111.92M
Capital expenditures 0.90M 0.10M 0.59M 1.02M 1.13M
Change receivables - - - -0.27200M -
Cash flows other operating - - - 13.00M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -170.53000M -
Change in working capital -6.47500M -9.20000M 7.47M -3.33500M -7.60400M
Stock based compensation 14.21M 25.49M 32.98M 42.38M 63.36M
Other non cash items 562.84M 50.85M -80.99300M 8.67M 16.06M
Free cash flow -103.57600M -82.53200M -84.70800M -105.49100M -64.37400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATAI
ATAI Life Sciences BV		 -0.28 5.82% 4.53 - - 437.09 8.05 374.98 0.27
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.

ATAI Life Sciences BV

250 West 34th Street, New York, NY, United States, 10119

Key Executives

Name Title Year Born
Mr. Christian Angermayer Founder & Chairman of the Supervisory Board 1978
Mr. Florian Brand Co-founder & CEO 1987
Dr. Srinivas G. Rao M.D., Ph.D. Co-Founder & Chief Scientific Officer 1969
Dr. Rolando Gutierrez-Esteinou M.D. Chief Medical Officer 1961
Mr. Gregory L. Weaver CPA, M.B.A. Non-Employee Advisor 1956
Mr. Stephen B. Bardin MD & CFO 1990
Mr. Frank Stegert VP of Investment & Venture Management 1981
Ms. Anne Johnson Chief Accounting Officer NA
Ms. Madison Crawford Sr. Mang. of Accounting NA
Mr. Aaqil Anwar Mang. of Corp. Fin. & Investor Relations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions